Opinion
Volume 1 Issue S1 - 2016
Critical Points Regarding Chronic Musculoskeletal Pain Management Using Analgesics in Elderly Patients
Toshihiro Imamura*
The Center for Research and Treatment of Bone and Joint Disease for Workers, Department of Orthopaedic Surgery, Kyushu Rosai Hospital, Japan Labour Health and Welfare Organization
*Corresponding Author: Toshihiro Imamura, The Center for Research and Treatment of Bone and Joint Disease for Workers, Department of Orthopaedic Surgery, Kyushu Rosai Hospital, Japan Labour Health and Welfare Organization.
Received: February 03, 2016; Published: February 03, 2016
Citation: Toshihiro Imamura. “Critical Points Regarding Chronic Musculoskeletal Pain Management Using Analgesics in Elderly Patients”. EC Orthopaedics 1.S1 (2016): S1-S4.
Abstract
Chronic musculoskeletal pain such as low back pain affects not only patients, but it also affects caregiver’s activity of daily life or quality of life. One approach to management of chronic pain is medication. However, chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) may produce gastrointestinal problems such as erosion or ulcer. NSAIDs also decrease the glomerular filtration rate. Therefore, it is also important to recognize that elderly patients are potentially suffering from chronic kidney disease (CKD), which is increasing in prevalence throughout the world. Furthermore, elderly patients tend to have comorbid diseases, i.e. hypertension, diabetic mellitus, or hyperlipidaemia. Therefore, it is important to consider drug-drug interactions and not just focus on reducing the chronic pain. For example, NSAIDs interfere with antihypertensive medications such as angiotensin-converting enzyme inhibitors (ACEI), ß-blockers, and diuretics. The combination of ACEI, diuretics, and NSAIDs comprise the so-called ‘triple whammy’, which produces clinically significant nephrotoxicity in CKD and is often unrecognized. To reduce NSAID-induced gastrointestinal or kidney problems, opioid analgesics have been more frequently prescribed than before; however, adverse effects, i.e. nausea, constipation, and withdrawal syndrome, are a concern. It is important to make an effort to determine the best “tailor-made” treatment for patients, because the medication needed to relieve the chronic musculoskeletal pain is quite different in each patient.
Keywords: Chronic musculoskeletal pain; Chronic kidney disease; Non-steroidal anti-inflammatory drugs; Opioid; Adverse effect
Abbreviations: CKD: chronic kidney disease; NSAID: non-steroidal anti-inflammatory drug; ACEI: angiotensin-converting enzyme inhibitors
Progressive aging of society
The population of elders is increasing throughout the world. In particular, Japan is the world’s top country for longevity. In a society experiencing progressive aging, there is still about a 10-year gap between the average life expectancy and healthy life expectancy. The number of osteoporosis and osteoarthritis is increasing. Additionally, musculoskeletal diseases are usually associated with chronic musculoskeletal pain. Chronic pain decreases physical activity and leads to locomotive syndrome. Therefore, chronic musculoskeletal pain is an important issue to be solved. Approximately 15% of the Japanese population suffers from moderate-severe chronic musculoskeletal pain persisting for at least 6 months (Nakamura., et al.). Furthermore, the number of solitary elderly adults is increasing. Inoue., et al. reported that people living alone showed a high score of psychological distress, which may influence the development and maintenance of chronic pain (Inoue., et al.).
The most important approach to understanding chronic musculoskeletal pain is to understand patients’ backgrounds. Listening to patient complaints and sometimes gathering information from the family helps to determine the appropriate treatment. Social factors and related psychological factors (including depression) thus appear to greatly affect chronic musculoskeletal pain (Ushida); vice versa, persistent chronic pain also may interfere with mental health and lead to a depressive state.
Consideration of comorbidities to stop the ‘Triple Whammy’
Multiple options are available for the clinical management of pain, most of which are usually centred on pharmacological therapy. However, nonpharmacologic options, i.e. exercise therapy, counselling, physiotherapy, or cognitive behaviour therapy, should also be considered; moreover,attention should be given to indicationsfor surgery as well as to its appropriate timing if it is necessary to treat acute and chronic pain.Elderly individuals usually take more than three medications to treat conditions such as hypertension, diabetic mellitus, or hyperlipidaemia.
Non-steroidal inflammatory drugs (NSAIDs) are analgesic medicationsthat alleviate chronic pain and lead to improvements in the patient’s quality of life. However, it is necessary to pay attention to adverse effects, including drug-drug interactions. One adverse effect of NSAIDs is gastrointestinal toxicity, which can be reduced through the use of proton pump inhibitors. In addition, the use of NSAIDs decreased following the implementation of estimated glomerular filtration rate. Recently,a cohort study showed that proton pump inhibitor use was associated with a higher risk of incident CKD (Lazarus., et al.).
Additionally, chronic NSAID use accelerates the progression of CKD (Imai., et al.). There are approximately 13,300,000 patients in Japan, or about 13% of the adult population, who have CKD stage G3a or above. Considering that the number of end-stage renal failure patients and dialysis patients increases annually, it is certainly not a rare pathology. This is especially true in the elderly population, in which there is potentially impaired renal function. Furthermore, the combination of angiotensin-converting enzyme inhibitors, diuretics, and NSAIDs comprise the so-called ‘triple whammy’, which produces clinically significant nephrotoxicity in CKD and is often unrecognized (Boyd, Mathew and Thomas; Onuigbo and Agbasi). This is a preventable condition if recognized.
Opioid use should be carefully monitored to avoid serious adverse effects
Opioid analgesics, such as tramadol and buprenorphine patch, alleviate chronic musculoskeletal pain and disability, while avoiding adverse effects such as gastrointestinal and renal toxicity (Imamura). Buprenorphine also shows a potential benefit in improving neuropathic pain symptoms, possibly owing to its specific pharmacological profile (Pergolizzi., et al.). Careful monitoring for toxicity and efficacy is critical, given that advanced age increases the risk for adverse effects. In particular, elderly patients may suffer from extra pyramidal symptoms.
Nausea and vomiting are well-known adverse effects of opioids. To reduce these adverse effects, antiemetic medications are often prescribed. However, certain antiemetic medications may worsen extra pyramidal symptoms; therefore, careful monitoring is required when administering these medications (Moos and Hansen).Moreover, the anticholinergic effect of opioids worsens cognitive function, especially in elderly patients. In addition, other common medications such as antihistamines also contain an anticholinergic agent. Anticholinergic activity is generally thought to cause cognitive dysfunction, which worsens adherence to prescribed medications.
In addition to the anticholinergic effect, withdrawal syndrome should also be considered. This has a high chance of occurring if patients stop taking tramadol suddenly because of adverse effects. The symptoms of tramadol withdrawal include anxiety and restlessness, autonomic dysfunction, abdominal cramping, diarrhoea, sleeplessness, migraine-like headaches, and myoclonic activity of the extremities (Barsotti, Mycyk and Reyes; Thomas and Suresh). Withdrawal of even low doses of tramadol (50 mg) has been associated withuncomfortable restless leg syndrome (Park., et al.). Various tramadol extended-releases (once-daily) formulations have been reported to have a lower incidence and severity of adverse events compared to those for immediate-release formulations (Mongin). Presumably, the weekly opioid, transdermal buprenorphine patch would have equivalent or less severity of adverse effects, including withdrawal symptoms.
One of the important keys for orthopaedic surgeons to improve strict patient adherence to prescribed medication is to prescribe as few analgesic medications as possible. Therefore, I personally prefer anextended -release formulation (tablet or patch) rather than an immediate-release opioid. Recently, an interesting paper was published in which transdermal buprenorphine was shown to be cost-effective compared to tramadol (Hirst., et al.), especially for female patients age 75 or older in whom there is a high risk of fracture. This is important, as tramadol has a higher risk of fracture than some other opioid analgesics used to treat moderate-to-severe pain.
Hepatic impairment is another point to be considered. Certain opioids such as codeine or tramadolrely on hepatic biotransformation to active metabolites. Accordingly, a possible reduction of their analgesic effect isan expected pharmacodynamic consequence of hepatic impairment. Buprenorphine has also been reported to possibly cause hepatotoxicity, potentially through direct mitochondrial toxicity(Zuin., et al.).Therefore, careful monitoring, at least a blood sample, is required, even for asymptomatic patients. For patients with hepatic impairment, I recommend a lower dose of tramadol and/or acetaminophen.
Rigorous research efforts are needed to better understand the clinical risk factors for these adverse drug reactions. Since chronic pain management is not straightforward, it is essential to determine the best way to provide a “tailor-made treatment” for patients.
Acknowledgements
This research was supported by research funds to promote the hospital functions of the Japan Labour Health and Welfare Organiza-tion.
Conflict of interest
There are no conflicts of interest to declare.
Bibliography
  1. Barsotti CE., et al. “Withdrawal Syndrome from Tramadol Hydrochloride”. American Journal of Emergency Medicine 21.1 (2003): 87-88.
  2. Boyd IW., et al. “Cox-2 Inhibitors and Renal Failure: The Triple Whammy Revisited”. Medical Journal of Australia173.5 (2000): 274.
  3. Hirst A., et al. “Tramadol and the Risk of Fracture in an Elderly Female Population: A Cost Utility Assessment with Comparison to Transdermal Buprenorphine”. The European Journal of Health Economics (2015).
  4. Imai E., et al. “Chronic Kidney Disease Japan Cohort (Ckd-Jac) Study: Design and Methods”. Hypertension Research31.6 (2008): 1101-1017.
  5. Imamura T. “Significant Efficacy of Tramadol/Acetaminophen in Elderly Patients with Chronic Low Back Pain Uncontrolled by Nsaids: An Observational Study”. The Open Orthopaedics Journal 9 (2015): 120-125.
  6. Inoue S., et al. “Chronic Pain in the Japanese Community--Prevalence, Characteristics and Impact on Quality of Life”. PLoS One 10.6 (2015): e0129262.
  7. Lazarus B., et al. “Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease”. JAMA Intern Med117.2 (2016): 238-246.
  8. Mongin G. “Tramadol Extended-Release Formulations in the Management of Pain Due to Osteoarthritis”. Expert review of neurotherapeutics7.12 (2007): 1775-1784.
  9. Moos., et al. “Metoclopramide and Extrapyramidal Symptoms: A Case Report”. Journal of Perianesthesia Nursing23.5 (2008): 292-299.
  10. Nakamura M., et al. “Prevalence and Characteristics of Chronic Musculoskeletal Pain in Japan”. Journal of Orthopaedic Science16.4 (2011): 424-432.
  11. OnuigboMA and N Agbasi. “Quadruple Whammy"- a Preventable Newly Described Syndrome of Post-Operative Aki in Ckd Ii and Ckd Iii Patients on Combination "Triple Whammy" Medications: A Mayo Clinic Health System, Eau Claire, Wisconsin Experience”. Nigerian Journal of Clinical Practice17.5 (2014): 649-654.
  12. Park YM., et al. “Acute-Withdrawal Restless Legs Syndrome Following Abrupt Cessation of Short-Term Tramadol”.  Psychiatry Investigation11.2 (2014): 204-206.
  13. Pergolizzi J., et al. “Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization Step Iii Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone)”. Pain Practice8.4 (2008): 287-313.
  14. Thomas AN and M Suresh. “Opiate Withdrawal after Tramadol and Patient-Controlled Analgesia”. Anaesthesia55.8 (2000): 826-827.
  15. Ushida T. “Burdensome Problems of Chronic Musculoskeletal Pain and Future Prospects”. Journal of Orthopaedic Science20.6 (2015): 958-966.
  16. Zuin M., et al. “Acute Liver and Renal Failure During Treatment with Buprenorphine at Therapeutic Dose”. Digestive and Liver Disease41.7 (2009): e8-e10.
Copyright: © 2016 Toshihiro Imamura. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


November Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 14, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.